Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome
Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.
Related Articles
China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
Guideline Task Force Nomination Application – American Society for Radiation Oncology (ASTRO)
ASTRO welcomes nominations for participation in upcoming practice guidelines. Please complete this form for consideration.
Novel HER2 TKI Shows Preliminary Activity in Breast Cancer Brain Metastases
Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.
Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel
Panelists discuss how the major unmet needs in treating synovial sarcoma include developing targeted therapies that effectively address the SS18::SSX fusion oncogene, improving early detection…
Addition of an immune checkpoint inhibitor reduces the risk of disease progression for select patients with anal cancer
Click on the article title to read more.
Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
Chandler Park, MD and Joshua Brody, MD discusses treatment challenges posed by the diverse spectrum of lymphomas, ranging from indolent subtypes, to aggressive diseases like…